27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Earlier today, Merus N.V. (NASDAQ:MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small cell lung cancer (NSCLC) and other solid tumors.
- Needham says that the first clinical data readout from MCLA-129 suggests that the drug has a clinical profile comparable to Johnson & Johnson's (NYSE:JNJ) Rybrevant (amivantamab).
- The analyst keeps the Buy rating and a price target of $45.
- Also Read: Needham Says Merus' ASCO Update On Zeno 'Positive'
- While available data are limited efficacy appears to be comparable, and MCLA-129 saw one ≥ Grade 3 infusion-related reaction, whereas the analyst had not seen any with amivantamab at the WCLC 2018 update.
- 13 patients were evaluable for response with preliminary signs of anti-tumor activity observed, including two partial responses (one confirmed) in EGFR mt NSCLC and four confirmed stable disease.
- The analyst says that while expectations for MCLA-129 have come down, with the stock down ~20% over the past month, investors were looking for a competitive clinical profile.
- Price Action: MRUS shares are up 1.71% at $19.66 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!